Be the first to like this.
0 comment(s).
No result.
1
5
save malaysia!
6
Good Articles to Share
Khamenei says US, Israel will 'receive a tooth-breaking response'
7
Good Articles to Share
LIVE: Donald Trump delivers remarks in the crucial swing state of Pennsylvania
8
#
Stock
Score
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock
Time
Signal
Duration
Stock
Time
Signal
Duration
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Posted by lextcs > 2017-02-02 10:11 | Report Abuse
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus. EnteroMedics Inc. (NASDAQ:ETRM) EnteroMedics Inc. has 1 year price target of $140. On Sep 16 EnteroMedics Inc. (NASDAQ:ETRM) reported its EPS in the last quarter as $-11.9/Share beating the analyst estimate of $-34.65/Share by the difference of $22.75. This showed the surprise of 65.7% in the last quarter earnings. For the Current Quarter, 1 analysts are projecting the mean EPS to be $-35/share. According to their observations and findings, the stock could provide a high EPS of $-35/share and a Low EPS of $-35/share. The 2 analysts offering 12-month price forecasts for EnteroMedicsInc have a median target of 77.00, with a high estimate of 140.00 and a low estimate of 14.00. The median estimate represents a +1,124.17% increase from the last price of 6.29. (CNN MONEY) Many Analysts provided their foresight on Revenue Estimates of EnteroMedics Inc. where they believe that the company has the potential to earn average revenue of $300 Million for the current quarter. According to their predictions High & Low revenue estimates are 300 Million and 300 Million respectively. EnteroMedics Inc. (NASDAQ:ETRM) topped its 52-week high price of $30.41 on Jan 10, 2017 and 52-Week Low Price of $0.04 on Dec 27, 2016. The Stock currently has the market capitalization of $22.08 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 10.38% and monthly volatility of 36.52% respectively. EnteroMedics Inc. Gross Margin percentage stands at 48% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 69.02% with the 50-Day Simple Moving Average of 69.02 percent. Currently, the company has SMA200 (200-day simple moving average) of 435.87 Percent. The Stock has YTD (year to date) performance of 214.5 percent. caveat emptor.... for those who likes the wild rides of ups and downs. as for apple they are heading to another share split soon...another no brainer to park our worthless ringgit into usd and let it grow.